Evogene (TSE:EVGN) receives a buy rating from Echelon Wealth Partners


Evogene (TSE: EVGN – Get a review)The stock had its “buy” rating reaffirmed by equity research analysts Echelon Wealth Partners in a research note released on Friday, TipRanks reports. They currently have a CA$10.00 price target on the stock.

About Evogene (Get a rating)

Evogene is a leading computational biology company focused on revolutionizing product discovery and development across multiple life science-based industries, including human health and agriculture, through the use of its widely applicable Computational Predictive Biology (CPB) platform. The CPB platform, integrating a deep understanding of biology through the power of big data and artificial intelligence, was designed to discover and computer-guide the development of life science products based on microbes, small molecules and genetic elements.

Featured Articles

Get news and reviews for Evogene Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Evogene and related companies with MarketBeat.com’s FREE daily newsletter.


Comments are closed.